Quantcast

Latest LIALDA Stories

2014-03-28 16:22:54

DUBLIN, March 28, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the United States Court of Appeals for the Federal Circuit has reversed a lower court ruling that Actavis' generic version of Shire's Lialda(®) (mesalamine extended-release tablets) infringes United States Patent No. 6,773,720 (the '720 Patent). The Appeals Court found that the U.S. District Court for the Southern District of Florida did not correctly construe the claims of the '720 Patent, and...

2013-09-24 23:19:33

Reportbuyer.com just published a new market research report: Inflammatory Bowel Diseases: World Drug Market 2013-2023. London (PRWEB) September 24, 2013 Report Details Medicines for bowel inflammation - you explore R&D and potential sales What's the future for treating inflammatory bowel diseases (IBD)? Visiongain's updated report gives you revenue predictions from 2013, helping you stay ahead. There you find financial results, R&D trends, opportunities, and potential...

2011-07-28 06:23:00

DUBLIN, July 28, 2011 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the three months to June 30, 2011. Financial Highlights Q2 2011(1) Product sales $993 million +30% Total revenues $1,063 million +25% Non GAAP operating income...

2011-07-18 06:00:00

PHILADELPHIA, July 18, 2011 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Lialda(R) (mesalamine) Delayed Release Tablets for the maintenance of remission in patients with ulcerative colitis. This approval is based on results from a six-month study demonstrating the safety and effectiveness of Lialda in maintaining endoscopic remission in adult...

2011-07-18 06:00:00

PHILADELPHIA, July 18, 2011 /PRNewswire/ -- Shire plc (LSE: SHP; NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Lialda® (mesalamine) Delayed Release Tablets for the maintenance of remission in patients with ulcerative colitis. This approval is based on results from a six-month study demonstrating the safety and effectiveness of Lialda in maintaining endoscopic remission in adult...

2011-04-28 05:00:00

DUBLIN, April 28, 2011 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the three months to March 31, 2011. Financial Highlights Q1 2011(1) Product sales $889 million +24% Total revenues $972 million +19% Non GAAP operating income $306 million +15%...

2010-08-04 06:31:00

DUBLIN, August 4, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to June 30, 2010. Financial Highlights Q2 2010(1) Product sales $764 million +37% Product sales from core products(2) $684 million +39% Product sales from core products on a CER basis(3) +42%...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin